Fox Chase Cancer Center Increases Issued Patents for Fiscal Years 2019 and 2020

PHILADELPHIA (September 17, 2020)—Fox Chase Cancer Center is pleased to announce that its scientists and clinicians earned several new patents during fiscal years 2019 and 2020, the latter of which ended June 30, 2020. The number of issued patents increased by 71% compared to fiscal years 2017 and 2018 cumulatively.

The inventors listed below in bold are currently employed at Fox Chase. The names that are not bolded are for inventors who previously worked for Fox Chase or co-inventors from other institutions. The patents, along with the inventors’ names and issue dates, are:

  • Astsaturov, Igor; Golemis, Erica A.; Serebriiskii, Ilya G.; and Weiner, Louis M.; “EGFR/NEDD9/TGF-β interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders,” US Patent# 10,450,613 B2, issued October 22, 2019.
  • Astsaturov, Igor; Khazak, Vladimir; and Serebriiskii, Ilya G.; “C-Myc as a biomarker for tumor sensitivity to treatment with RNA polymerase II inhibition,” US Patent# 10,328,050 B2, issued June 25, 2019.
  • Bellacosa, Alfonso; Tricarico, Rossella; Yen, Timothy J.; Bhattacharjee, Vikram; Mancuso, Pietro; Larue, Lionel; and Davidson, Irwin; “Closantel in combination with temozolomide for use in the treatment of a cancer in which is thymine DNA glycosylase expressed,” European Patent# EP3052655 B1, issued November 7, 2018.
  • Bellacosa, Alfonso; Yen, Timothy J.; Beeharry, Neil; Smith, Mitchell; Tricarico, Rossella; Bhattacharjee, Vikram; and Mancuso, Pietro; “Combination of DNA repair inhibition with bendamustine or gemcitabine in the treatment of cancer,” US Patent# 10,220,051 B2, issued March 5, 2019.
  • Cheng, Hong and Roder, Heinrich; “Carbon-detected NMR for mapping binding sites in intrinsically disordered regions of a protein,” US Patent# 10,436,795 B2, issued October 8, 2019.
  • Chernoff, Jonathan and Chow, Hoi Yee; “P21-activated kinase inhibitor domain targeted transgenic mouse,” US Patent# 10,584,353 B2, issued March 10, 2020.
  • El-Deiry Wafik, S.; Tian, Xiaobing; and Zhang, Shengliang; “Prodigiosin analogs,” US Patent# 10,654,801 B2, issued May 19, 2020.
  • Testa, Joseph R.; Carbone, Michele; Cheung, Mitchell; and Pei, Jianming; “Methods for diagnosing a predisposition to develop cancer,” US Patent# 10,344,333 B2, issued July 9, 2019.
  • Tokar, Jeffrey and Yeung, Anthony T.; “Biomarkers for the diagnosis and treatment of pancreatic cancer,” Canadian Patent# 2,712,505, issued October 23, 2018.
  • Tulin, Alexei; “Screening assay for identification of poly(ADP-ribose) polymerase 1 inhibitors,” US Patent# 10,550,108 B2, issued November 12, 2019.
  • Tulin, Alexei; “Poly(ADP-ribose) polymerase 1 inhibitors structurally unrelated to NAD,” US Patent# 10,472,664 B2, issued February 4, 2020.
  • Yen, Timothy J. and Bhattacharjee, Vikram; “Combined inhibition of the Vitamin D receptor and poly(ADP) ribose polymerase (PARP) in the treatment of cancer,” US Patent# 10,449,200 B2, issued October 22, 2019.

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427